Gyre Therapeutics closed its $300 million acquisition of Cullgen on Tuesday, adding a protein degradation platform and a pipeline of molecular glue and PROTAC candidates to its existing small-molecule oncology programs. The transaction, first announced in late December, gives Gyre immediate access to preclinical degrader assets targeting previously undruggable proteins, along with Cullgen's proprietary screening libraries and a team of 47 protein degradation specialists.
Cullgen brought two lead programs into the deal: a molecular glue degrader targeting transcription factors in solid tumors, currently in IND-enabling studies, and a cereblon-based PROTAC for hematologic malignancies expected to file an IND in H2 2025. Gyre also gains Cullgen's dcGRID screening platform, which maps degrader-target interactions across 2,800 E3 ligase-substrate pairs, a dataset that took Cullgen four years to compile. The platform has already identified 12 novel E3 ligase binders, three of which Gyre intends to advance into lead optimization by year-end. Gyre paid $180 million in cash at close, with $120 million in milestone payments tied to three regulatory filings and one commercialization event through 2028.
The acquisition positions Gyre as one of the few mid-cap biotechs with both traditional kinase inhibitors and next-generation protein degraders under one roof. Protein degradation has emerged as the preferred modality for targets resistant to occupancy-driven inhibition, particularly transcription factors and scaffolding proteins that lack enzymatic active sites. The global PROTAC market is projected to reach $14.2 billion by 2032, growing at a 38% CAGR, according to Roots Analysis. Gyre's existing pipeline includes a KRAS G12C inhibitor in Phase 2 trials and a CDK4/6 inhibitor in Phase 1, both of which could eventually be paired with Cullgen's degraders in combination regimens. The company now holds 22 issued patents in protein degradation chemistry, a portfolio that extends its composition-of-matter protection through 2041 for lead candidates.
Allocators should track Gyre's IND filings for the two Cullgen programs, expected in Q2 and Q4 2025 respectively, as clinical readouts will determine whether the platform translates into differentiated efficacy. Watch for updates on Gyre's cash runway; the company reported $487 million in cash as of December 31, enough to fund operations into Q3 2026 without additional financing. Partnership discussions with large-cap pharma are likely, particularly around the cereblon PROTAC, which competes in a crowded space against Bristol Myers Squibb's CC-92480 and Kymera's KT-333. Gyre's next earnings call is scheduled for May 8, where management will detail integration milestones and provide updated guidance on the combined pipeline.
The Cullgen team remains intact and relocates to Gyre's San Diego headquarters in Q2, preserving the protein degradation expertise that justified the premium valuation.